Table 5 Follow-up materials in the LMV group
The follow-up materials | 1 month after treatment (n1 = 10) | 3 months after treatment (n2 = 9) | 6 months after treatment (n3 = 8) | 12 months after treatment (n4 = 4) |
|---|---|---|---|---|
Clinical manifestations | None | 1 case had vomiting again | 2 cases had new rash | 2 cases had vomiting and diarrhea again |
WBC (× 109/L) | 8.73 ± 3.35 | 7.71 ± 2.88 | 5.55 ± 2.12 | 4.35 ± 3.38 |
HGB (g/L) | 125.10 ± 15.13 | 135.50 ± 22.25 | 129.38 ± 16.28 | 128.4 ± 12.97 |
PLT (× 109/L) | 212.40 ± 19.83 | 238.13 ± 41.73 | 255.00 ± 34.57 | 253.00 ± 54.09 |
C3 (g/L) | 0.74 ± 0.24 | 0.89 ± 0.17 | 0.82 ± 0.13 | 0.68 ± 0.23 |
C4 (g/L) | 0.12 ± 0.05 | 0.16 ± 0.06 | 0.15 ± 0.05 | 0.12 ± 0.09 |
24-h urine protein quantification (mg/d) | 151.13 ± 109.54 | 1484.94 ± 2322.15 | 1511.54 ± 1814.48 | 801.98 ± 1069.25 |
SLEDAI-2 K | - | 2.25 ± 1.25 | 4.50 ± 3.93 | 8.00 ± 5.34 |
The positive rate of anti-dsDNA antibody (%) | 71.4 | 37.5 | 50.0 | 75.0 |
Abdominal-enhanced CT | Normal (3 cases) | Normal (2 cases) | Normal (2 cases) | 1 case: normal 2 cases: intestinal wall thickening |